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Abstract
Given the current bacterial resistance crisis, antimicrobial stewardship programmes are of the utmost importance. We present a narrative
review of the impact of infectious disease specialists (IDSs) on the quality and quantity of antibiotic use in acute-care hospitals, and discuss
the main factors that could limit the efﬁcacy of IDS recommendations. A total of 31 studies were included in this review, with a wide range
of infections, hospital settings, and types of antibiotic prescription. Seven of 31 studies were randomized controlled trials, before/after
controlled studies, or before/after uncontrolled studies with interrupted time-series analysis. In almost all studies, IDS intervention was
associated with a signiﬁcant improvement in the appropriateness of antibiotic prescribing as compared with prescriptions without any IDS
input, and with decreased antibiotic consumption. Variability in the antibiotic prescribing practices of IDSs, informal (curbside) consultations
and the involvement of junior IDSs are among the factors that could have an impact on the efﬁcacy of IDS recommendations and on
compliance rates, and deserve further investigation. We also discuss possible drawbacks of IDSs in acute-care hospitals that are rarely
reported in the published literature. Overall, IDSs are valuable to antimicrobial stewardship programmes in hospitals, but their impact
depends on many human and organizational factors.
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“Even with my great personal loyalties to infectious disease, I
cannot conceive a need for 300 more infectious-disease
experts unless they spend their time culturing each other”
[1].
Introduction
Infectious disease (ID) specialists (IDSs), clinical microbiolo-
gists and pharmacists are key actors in hospital-based antimi-
crobial stewardship (AMS) programmes (AMSPs), and
multidisciplinary antimicrobial management teams are recom-
mended [2]. Wide variations in IDS training and type of
practice exist across the globe [3–5]. The added value of IDSs
for AMSPs has been uncertain, but is now being increasingly
acknowledged [6–8]. In contrast, the positive impact of
antimicrobial management teams has been largely demon-
strated in the literature; less data are available regarding clinical
microbiologists and pharmacists [9].
To the best of our knowledge, no comprehensive
literature review on the impact of IDSs on antibiotic
prescribing has been published so far. We therefore aimed
to review the impact of IDSs on the quality and quantity of
antibiotic prescriptions in acute-care hospitals, and discuss
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the main factors that can limit the efﬁcacy of IDS
recommendations.
How do Clinicians Perceive IDSs?
Despite frequent requests by clinicians for IDS advice [10,11],
only a few quantitative surveys have assessed the perceptions
of clinicians regarding the usefulness of IDS consultations
[12–16], and only one was speciﬁcally dedicated to this topic
[13]. All of these studies were conducted in settings where
AMSPs involving IDSs have been in place for a long time.
In a survey administered to junior doctors at the Johns
Hopkins Hospital in Baltimore (USA), IDSs were considered to
be useful sources of continuing medical education on antimi-
crobials by 96% (172/179) of the respondents [15]. When
asked about the factors that could inﬂuence their antibiotic
prescribing, 85% (104/123) of senior doctors in Nice (France)
cited IDSs, as did 70% (132/189) of junior doctors in Nice, and
62% (38/61) of junior doctors in Dundee (UK) [12,14]. Advice
from an IDS was considered by almost all respondents to be a
helpful intervention to improve antibiotic prescribing [12,14].
In an Australian survey, most intensivists (64%, 51/80)
indicated that they would seek advice from the ID/clinical
microbiology team when in doubt about antibiotic use [16].
Finally, in a hospital-wide survey in Grenoble (France), the
respondents expressed great satisfaction regarding ID consul-
tations that they requested principally to assist in medical
decision-making and to improve patient care [13].
Compliance with IDS advice in practice by clinicians implies
a positive perception of the usefulness of IDS advice. In the
literature, compliance rates range from 35% to >90% [17–33].
As compliance with IDS recommendations has been shown to
be associated with improved patient outcomes [18,19,34],
ensuring the best possible compliance is important.
Evidence of an Impact of IDSs on Antibiotic
prescribing
Literature review: methods
In order to evaluate the impact of IDSs on antibiotic
prescribing, we performed a narrative review. The literature
was reviewed independently by three authors, using the
PubMed database and searching for papers published in English,
French or German from 1 January 1980 to 31 September 2013.
The search terms used were (‘infectious diseases’ OR
‘infectious disease’) AND (specialist(s) OR physician(s) OR
consultation(s) OR consultant(s) OR consult(s) OR expert(s)
OR recommendation(s)) AND (antibiotic(s) OR antimicrobial
(s)). Of the 3754 results obtained, 65 titles were deemed to be
relevant to the impact of IDSs on antibiotic prescribing in
acute-care hospitals. The reference lists of these papers were
further searched to identify additional potentially relevant
studies for inclusion.
The goal of this review was to describe the impact of IDSs
on the appropriateness of antibiotic treatments and the
consumption of antibiotics. Outcome measures such as impact
on diagnosis, length of stay, mortality, antibiotic costs and
bacterial resistance did not constitute the primary endpoint of
the review, but will be discussed where appropriate. We
included both observational studies and interventional studies
comparing an IDS intervention with no IDS intervention, with
no other AMS-type intervention implemented at the same
time. We limited our review to studies within acute-care
hospitals, and no restrictions were applied with regard to
characteristics of infections or patients.
Literature Review: Results
A total of 31 articles were included in this narrative review: 21
included patients with diverse infections (Table 1) and ten
focused on bacteraemia (Table 2) [17,20–22,27,28,35–59].
The diversity of the geographical sources of the studies
included in this review reﬂects the fact that, since the 1990s,
IDSs have had to prove their value worldwide; approximately
half of the studies came from the USA, France, and Turkey.
The types of IDS intervention varied with the studies, as did
the types of antibiotic prescription targeted by the IDSs
(prophylaxis; empirical or documented curative treatments;
and initiation or reassessment of treatment).
Several deﬁnitions of the appropriateness of antibiotic
treatment were used, with the assessment being based on
antibiotic susceptibility testing [21,27,55,56], on compliance
with guidelines [22,38,49–54,57], or on a more complex
algorithm [20,28,35,37,40,44,45]. In most studies, IDSs them-
selves assessed the appropriateness of antibiotic prescriptions
[20,22,35,37,38,40,45,50–52], which constitutes a potential
bias. In a few cases, the outcome measure was assessed by
IDSs blinded to the intervention group or to the prescriber
[35,37,38,52], and several assessors reviewed the prescrip-
tions [20,38,40,45,50,52].
IDS intervention was associated with a signiﬁcant improve-
ment in the appropriateness of antibiotics in almost all studies, as
compared with prescriptions without any IDS input (Tables 1
and 2) [20–22,28,35,37,40,44,45,49–57]. This positive impact
was observed accross a wide range of infections, hospital
settings, and types of antibiotic prescription. In two studies, IDS
intervention was not found to improve signiﬁcantly the appro-
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priateness of antibiotic prescriptions [27,38], despite a trend;
this was possibly attributable to a lack of statistical power,
considering the small number of patients included [38], or to
suboptimal compliance with IDS advice [27].
Beyond an improvement in the quality of antibiotic
prescriptions, several studies also showed an impact of IDSs
on the quantity of antibiotics prescribed, usually measured as
deﬁned daily doses/100 patient-days or days of therapy
(Table 1). Nearly all studies showed a reduction in antibiotic
use [22,36,41–43,45–48,58,59].
Literature Review: Discussion
Our review provides evidence from around the globe, and in
many clinical situations, that IDSs can be effective in reducing
the antibiotic exposure of patients and increasing the quality of
antibiotic use, with no adverse effects on other patient
outcomes (Tables 1 and 2). As seven of 31 studies had a design
that complied with the Cochrane Effective Practice and
Organization of Care Group recommendations (randomized
controlled trial, before/after controlled study, or before/after
uncontrolled study with interrupted time-series analysis;
available at http://epoc.cochrane.org/sites/epoc.cochrane.org/
ﬁles/uploads/datacollectionchecklist.pdf), the quality of evi-
dence can be categorized as moderately high.
Beyond the impact of IDSs on antibiotic use, several studies
also showed that IDS intervention was associated with reduced
length of stay [22,36,42], decreased mortality [22,52–54,56,57],
a reduction in the prevalence of multiresistant bacteria [41,58],
and a reduction in the overall costs of antibiotics
[36,41,45,47,48,58]. This cost-saving impact was particularly
important when IDSs were totally responsible for the pre-
scriptions of antibiotics [36], and was shown to compensate for
the annual salary of the IDS [41,48]; however, it is important to
recognize that the majority of antibiotics prescribed are
increasingly generics, so the impact on cost is likely to be
lower in clinical practice than seen in studies over the past two
decades. Recently, Schmitt et al. provided high-quality data on
the positive impact of IDSs on mortality, re-admission rates,
and healthcare costs, all the more so as patients received early
(within 2 days of admission) IDS intervention [6,60].
Factors that could Reduce the Impact of
IDSs within an AMSP
The literature review shows that IDSs are good AMSP leaders
in general. However, there is likely to be a publication bias, as
studies that found no impact or even a deleterious effect ofT
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IDSs on antibiotic prescribing were rarely reported in the
literature. Moreover, we are not aware of any controlled study
that has shown a correlation between the number of IDSs in a
country and the level of antibiotic use and associated
resistance in hospitals. Importantly, contradictory scenarios
are possible. For instance, Germany had, until the late 1990s, a
much lower density of IDSs but also more prudent antibiotic
prescribing patterns than the USA [61]. Likewise, Israel and
Turkey, countries with high densities of IDSs, have not been
protected against antibiotic misuse and hyperendemic multi-
resistant microorganisms in healthcare institutions [62]. In
contrast, the introduction of a new healthcare regulation in
Turkey in 2003 requiring mandatory approval of speciﬁc
parenteral intravenous antibiotics by dedicated IDSs showed
some health economic beneﬁts [58,59].
The impact of IDSs on antibiotic prescribing in hospitals
depends on a complex combination of factors, among them the
IDS characteristics (e.g. expertise, experience in the ﬁeld of
AMS, and communication and teaching skills), the prescriber,
the healthcare system organization, and the culture within the
hospital and the department. It has already been shown that
human and organizational factors play a major role in prescrib-
ing behaviour [63], and they probably account for much of the
variation in compliance with IDS recommendations observed in
the literature. Computerized decision support systems may
complement the IDS service to decrease therapeutic uncer-
tainty and increase the adequacy of antibiotic therapy. This
possible synergy has not been formally evaluated, however.
We will discuss here the main IDS-related factors that could
limit the impact of IDS interventions within an AMSP. First, there
can be considerable variability in the antibiotic prescribing
practices of IDSs, particularly if they had received training at
different institutions, and especially for situations in which
evidence-based recommendations are missing or local antimi-
crobial guidelines do not exist [64–67]. In a hospital in Singapore,
IDSs and a prospective audit and feedback AMSP operated
independently, with different therapy-modifying recommenda-
tions being offered for the same inpatients in 19% (143/756) of
the cases [68]. Moreover, conﬂicts of interest can occur
between any prescriber, including the IDSs, and the pharma-
ceutical industry [69,70]. Perverse incentives might encourage a
small subgroup of IDSs to excessively promote the use of new
antibiotics. The increased penetration of ID consultations is a
good thing. However, they should not replace an AMSP,
including a dedicated antimicrobial management team [9]. In a
US tertiary-care hospital, expenditure on antimicrobials
decreased signiﬁcantly after implementation of an AMSP, but
increased when this programme was discontinued, even though
the IDS consultation service was reinforced at that time and
encouraged to promote judicious antibiotic prescribing [71].
Second, informal consultations (also known as curbside
consultations) can pose speciﬁc problems. Informal consulta-
tions can be performed by telephone or e-mail, without direct
patient contact. They are widely used by IDSs, and the number
of curbside consultations often approaches or exceeds the
number of formal consultations [10,72,73]. A prospective US
study demonstrated that informal consultations represented a
signiﬁcant amount of work, were complex in nature, and had a
high relative value [73]. They have certain drawbacks, including
the lack of direct compensation for the IDS, an increased risk
of legal liability, and potential inaccuracy and incompleteness of
the information exchanged. In a retrospective observational
study conducted in a US hospital, 39% (67/173) of telephone
calls received by the AMS team (ID fellows and/or senior
pharmacists) for prior approval contained clinically relevant
inaccuracies [74]. The same authors showed that inaccurate
communication of patient data, particularly microbiological
data, during prior-approval calls was associated with an
increased risk of inappropriate antimicrobial recommendations
from the AMS team [75]. In a retrospective observational
study in one hospital in Finland, informal IDS consultations by
telephone were associated with higher 90-day mortality for
Staphylococcus aureus bacteraemia than bedside consultations
in multivariate analysis (OR 2.31) [57]. Although telephone
consultation was inferior to bedside consultation, it was
superior to not consulting at all: an absence of IDS consulta-
tion led to an even poorer outcome (OR 3.56) [57]. A lack of
valid information for the IDS and poor compliance with the
advice given by the IDS may be reasons for the poorer
outcome with telephone consultation than with bedside
consultation in this S. aureus bacteraemia study. There is,
however, observational evidence that informal consultations
for various reasons result in levels of compliance with
recommendations that are comparable to the levels seen for
formal recommendations, without any difference in patient
outcomes, including mortality [31]. Informal consultations may
require more experience than formal consultations, explaining
why residents were less likely to provide informal consulta-
tions than a senior IDS in a French hospital [31]. For any
consultation, formal or informal, IDSs should directly verify
patient data critical to their recommendations (e.g. culture
susceptibility results); electronic medical records are helpful in
this respect. Teleconsultation by use of a web platform can
also been used, and proved to be successful in a small, remote
community hospital in Brazil, with 100% compliance with the
recommendations made by the IDS, and full recording of all
exchanged information [29].
Finally, although ID trainees are increasingly involved in
AMS, few studies have assessed the appropriateness of and
level of compliance with their recommendations. In a hospital
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in Turkey, formal consultations performed on their own by
seven ID trainees on the night shift and at the weekends were
considered to result in appropriate antibiotic prescriptions by
a senior IDS in 98% (319/327) of the cases, and requesting
physicians complied with the recommendations in 75%
(418/555) of the cases [32]. However, in a French hospital
where recommendations given by the ID resident were always
supervised by a senior board-certiﬁed IDS, advice was more
frequently followed when it was given by the senior IDS [30].
In a hospital in Singapore, a prospective-audit-and-feedback
AMSP for haematology and oncology inpatients was switched
from one led by a dedicated senior IDS to one performed by a
rotating team of four unsupervised ID trainees [33]. The
compliance rate fell signiﬁcantly during the year, with an
accompanying increase in antibiotic use. The trends were
reversed only upon reversion to the original set-up. Trainees’
recommendations were sometimes suboptimal, and the
weekly rotation of trainees resulted in conﬂicting recommen-
dations to the primary teams on occasion, reducing their
credibility [33]. In another French study, ID trainees were
often less well perceived than a senior IDS by the requesting
physicians, particularly senior ones [76]. It is therefore
essential to have structured AMS training programmes for
ID trainees, under the supervision of senior IDSs who may
more easily overrule antagonistic colleagues [77].
Conclusions
The vibrant editorial written by Kunin in 1997 still sounds true
today: ‘There is only a thin red line of infectious disease
physicians who have dedicated themselves to rational antibiotic
therapy and control of hospital infections. The issues need to be
presented forcefully to the medical community and the third
party payermust get themessage that these programs saves lives
as well as money’ [78]. Our review strongly argues for the added
value of IDSs for AMS in hospitals. Their impact is likely to be
greater when a multidisciplinary AMS team is actively involved.
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